Skip to main content

Table 4 Quantitative parameters of the background and lesions in the exploration cohort

From: Optimizing acquisition times for total-body positron emission tomography/computed tomography with half-dose 18F-fluorodeoxyglucose in oncology patients

Measurement G15 G8 G5 G3 G2 G1
Liver SUVmax 3.00 ± 0.52 2.98 ± 0.47 3.09 ± 0.49 3.19 ± 0.50* 3.28 ± 0.53* 3.53 ± 0.60*
Liver SD 0.084 ± 0.063 0.124 ± 0.055 0.166 ± 0.070* 0.198 ± 0.072* 0.236 ± 0.074* 0.317 ± 0.100*
Liver SNR 40.98 ± 15.48 26.22 ± 12.19 19.02 ± 6.89* 15.70 ± 5.79* 13.16 ± 5.25* 9.66 ± 3.56*
Liver COV 0.030 ± 0.023 0.046 ± 0.019 0.061 ± 0.025* 0.072 ± 0.025* 0.086 ± 0.027* 0.114 ± 0.033*
Mediastinal SUVmax 2.27 ± 0.37 2.30 ± 0.37 2.33 ± 0.40 2.41 ± 0.43* 2.49 ± 0.45* 2.61 ± 0.50*
Mediastinal SD 0.118 ± 0.049 0.144 ± 0.047* 0.154 ± 0.039* 0.171 ± 0.045* 0.196 ± 0.054* 0.249 ± 0.083*
Lesion SUVmax 9.99 ± 7.94 11.60 ± 9.82 11.68 ± 9.92 12.01 ± 10.25* 12.06 ± 10.23* 12.27 ± 10.42*
Lesion SUVpeak 8.27 ± 6.46 9.01 ± 7.40 8.99 ± 7.36 9.01 ± 7.41 9.07 ± 7.42 8.98 ± 7.51
TBR 3.65 ± 3.11 4.39 ± 3.93* 4.39 ± 3.96* 4.51 ± 4.13* 4.51 ± 4.09* 4.51 ± 4.06*
  1. The measured sample sizes for the background and lesion were 46 and 56, respectively
  2. SUVmax maximum standardized uptake value; SD standard deviation; SNR signal-to-noise ratio; COV coefficient of variation; SUVpeak peak standardized uptake value; TBR tumor-to-background ratio.
  3. Data are presented as mean ± standard deviation (mean ± SD)
  4. *Significant difference in comparison with the control group (G15), p < 0.05